| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441386 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Andrew Rowland, Mafalda M. Dias, Michael D. Wiese, Ganessan Kichenadasse, Ross A. McKinnon, Christos S. Karapetis, Michael J. Sorich,